Eye institute and Dainippon to develop iPS cell-based therapies

04/1/2013 | Genetic Engineering & Biotechnology News

Retina Institute Japan will receive about $16 million in an investment from Dainippon Sumitomo Pharma as part of a deal to work on new induced pluripotent stem cell-based therapies. The investment will give Dainippon a 5% stake in the institute. The partnership's focus will include treatments for refractory retinal disease and age-related macular degeneration.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Economics & Reimbursement Manager - Transcatheter Heart Valve
Edwards Lifesciences
Irvine, CA
Sr. Medical Device Reimbursement Specialist - Regional
Alcon
Fort Worth , TX
Assistant General Counsel/Senior Corporate Counsel - Healthcare Law Group
Genentech
94080, CA
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA